Caitlin Costello
University of California, San Diego
84 Papers
179 Citations
Caitlin Costello is an academic researcher from University of California, San Diego. The author has contributed to research in topics: Medicine & Multiple myeloma. The author has an hindex of 19, co-authored 54 publications. Previous affiliations of Caitlin Costello include Ohio State University.
Chat about Author
Papers
Newly diagnosed multiple myeloma: making sense of the menu.
TL;DR: In this paper , the authors evaluated the current treatment options and strategies for the management of NDMM using the best available data to provide a rationale for these decisions and found that there has been increasing overlap in the induction strategies used for all patients with NDMM, which increasingly provide the ultimate goal of deep and durable remissions.
Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Final Analysis of Griffin Among Clinically Relevant Subgroups
Ajai Chari,Jonathan L. Kaufman,Jacob P. Laubach,Douglas W. Sborov,Brandi Reeves,Cesar Rodriguez,Rebecca Silbermann,Luciano J. Costa,Larry D. Anderson,Nitya Nathwani,Nina Shah,Naresh Bumma,Sarah A. Holstein,Caitlin Costello,Andrzej Jakubowiak,Tanya M. Wildes,Robert Z. Orlowski,K. Shin,Andrew J. Cowan,Huiling Pei,Annelore Cortoos,Sharmila Patel,Thomas S. Lin,Paul G. Richardson,Saad Usmani,Peter M. Voorhees +25 more
TL;DR: Voorhees et al. as mentioned in this paper presented an end-of-study post hoc analysis of clinically relevant subgroups in the randomized phase 2 GRIFFIN trial (NCT02874742) (median follow-up, 13.5 mo), which met the pre-specified 1-sided α of 0.068.
Multiple myeloma, version 2.2016: Clinical practice guidelines in oncology
Kenneth C. Anderson,Melissa Alsina,Djordje Atanackovic,J. Sybil Biermann,Jason C. Chandler,Caitlin Costello,Benjamin Djulbegovic,Henry C. Fung,Cristina Gasparetto,Kelly N. Godby,Craig C. Hofmeister,Leona Holmberg,Sarah A. Holstein,Carol Ann Huff,Adetola A. Kassim,Amrita Krishnan,Shaji Kumar,Michaela Liedtke,Matthew A. Lunning,Noopur Raje,Seema Singhal,Clayton A. Smith,George Somlo,Keith Stockerl-Goldstein,Steven P. Treon,Donna M. Weber,Joachim Yahalom,Dorothy A. Shead,Rashmi Kumar +28 more
TL;DR: The NCCN Clinical Practice Guidelines in Oncology included in this issue address management of patients with solitary plasmacytoma and newly diagnosed MM.
Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient-reported outcomes from GRIFFIN.
Rebecca Silbermann,Jacob P. Laubach,Jonathan L. Kaufman,Douglas W. Sborov,Brandi Reeves,Cesar Rodriguez,Ajai Chari,Luciano J Costa,Larry D. Anderson,Nitya Nathwani,Nina Shah,Naresh Bumma,Sarah A Holstein,Caitlin Costello,Andrzej Jakubowiak,Robert Z. Orlowski,K. Shin,Andrew J Cowan,Katharine S. Gries,Huiling Pei,Annelore Cortoos,Sharmila Patel,Thomas S. Lin,Peter M. Voorhees,Saad Z Usmani,Paul G Richardson +25 more
TL;DR: Improvements in health-related quality of life contribute to the totality of evidence supporting the improvement in clinical outcomes such as response rates and PFS with D-RVd in induction, consolidation, and maintenance therapy in TE patients with NDMM.
Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance Therapy
Jonathan L. Kaufman,Jacob P. Laubach,Douglas W. Sborov,Brandi Reeves,Cesar Rodriguez,Ajai Chari,Rebecca Silbermann,Luciano J. Costa,Larry D. Anderson,Nitya Nathwani,Nina Shah,Yvonne A. Efebera,Sara A. Holstein,Caitlin Costello,Andrzej Jakubowiak,Tanya M. Wildes,Robert Z. Orlowski,Kenneth H. Shain,Andrew J. Cowan,Yana Lutska,Padma Bobba,Huiling Pei,Jon Ukropec,Jessica Vermeulen,Thomas S. Lin,Paul G. Richardson,Peter M. Voorhees +26 more
TL;DR: DARA plus RVd (D-RVd) significantly improved rates of stringent complete response (sCR) by the end of post-transplant consolidation therapy versus RVd and rate of minimal residual disease (MRD) negativity assessed by next-generation sequencing (clonoSEQ; Adaptive Biotechnologies).